Home » Cracked Vials Lead to Suspension of Dosing in Anthera Lupus Trial
Cracked Vials Lead to Suspension of Dosing in Anthera Lupus Trial
Cracked vials may set back Anthera Pharmaceuticals’ development plans for its lupus candidate, A-623. The company decided to suspend enrollment and dosing in the Phase IIb PEARL-SC trial after a site in the U.S. reported a number of cracked vials of the study product. A preliminary inspection of the site’s inventory and product storage facilities revealed the cracking was not an isolated problem, Anthera CEO Paul Truex said in a conference call.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May